News

The study will be conducted at the Winnipeg Clinic under the guidance of principal investigator, urologist, Patrick Cho. Samples collected from the study will be tested using recently

iSONEP is the ocular formulation of a monoclonal antibody that targets sphingosine-1-phosphate (S1P), a bioactive lipid that is dysregulated in cancer and other disorders of inappropriate angiogenesis and

The new broad agreement aims to deepen the already long-standing relationship between Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) and WuXi PharmaTech. WuXi, already a preferred research

The financing was led by new investor New Enterprise Associates (NEA), a global healthcare and technology venture capital firm, with additional new participation from Kaiser Permanente Ventures, an

The appointment increases the board to six members, five of whom are non-employee directors. Mr Brooksby is currently CFO of InNexus Biotechnical, a publicly traded drug development company.

Echo’s Symphony transdermal continuous glucose monitoring (tCGM) system is in late-stage development for both the diabetes home use and hospital critical care settings. Symphony incorporates Echo’s new Prelude

Pirfenidone was developed in Japan for the treatment of idiopathic pulmonary fibrosis (IPF) by Shionogi, which has rights to pirfenidone in Japan, Taiwan and South Korea. InterMune has

A study is currently being conducted in the US wherein the site is actively screening and enrolling subjects. The protocol for the study is an open-label, two-treatment, two-period,

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics